Science Corporation is a Vision & Sensory Prosthetics company founded in 2021 and based in Alameda, United States. It has raised $490M in total funding, most recently a Series C in 2026 at a $1.5B valuation.
| Date | Stage | Amount | Valuation | Lead investors |
|---|---|---|---|---|
| Mar 5, 2026 | Series C | $230M | — | Khosla Ventures, Lightspeed Venture Partners |
| Apr 14, 2025 | Series B | $104M |
| — |
| Khosla Ventures |
| May 23, 2024 | Series B | $26M | — | Khosla Ventures, Y Combinator |
No articles ingested yet for Science Corporation. Once the hourly news pipeline is live, every article the classifier tags as mentioning this company appears here with its one-line AI summary and sentiment.
A subretinal photovoltaic implant for patients blinded by geographic atrophy (late-stage dry age-related macular degeneration). Tiny silicon chips are placed under the retina during a 1-hour surgery; they convert near-infrared light from augmented-reality glasses into electrical stimulation of surviving bipolar cells. A NEJM-published 2025 study in 38 patients showed ~80% achieving significant visual acuity improvement at one year. Acquired from Pixium Vision in 2024; in FDA pivotal trial.
An investigational retinal implant that pairs optogenetic gene therapy — sensitizing surviving retinal cells to light — with an ultra-thin implanted microLED display placed over the retina, initially targeting retinitis pigmentosa and later dry age-related macular degeneration. Unlike PRIMA's photovoltaic approach, it aims to drive the retina directly via genetically introduced light-sensitive proteins.
18 patents on file, but none with both an extractable figure and an abstract on Google Patents yet.